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Abstract:  
Aims: Epidemiological evidence suggests that adipokines may be associated with the onset of 
type 2 diabetes, but the evidence to date is limited and inconclusive. This study examined the 
association between adiponectin and leptin and the subsequent diagnosis of type 2 diabetes in 
a UK population based cohort of non-diabetic middle-aged men. 
Methods: Baseline serum levels of leptin and adiponectin were measured in 1839 non-
diabetic men aged 50-60 years who were participating in the prospective population-based 
PRIME study. Over a mean follow-up of 14.7 years, new cases of type 2 diabetes were 
determined from self-reported clinical information with subsequent validation by general 
practitioners.   
Results: 151 participants developed type 2 diabetes during follow-up.  In Cox regression 
models adjusted for age, men in the top third of the leptin distribution were at increased risk 
(hazard ratio (HR) 4.27, 95%CI 2.67–6.83) and men in the top third of the adiponectin 
distribution at reduced risk (HR 0.24, 95%CI 0.14–0.42) relative to men in the bottom third.  
However, significance was lost for leptin after additional adjustment for BMI, waist to hip 
ratio, lifestyle factors and biological risk factors, including C-reactive protein (CRP).  Further 
adjustment for HOMA-IR also resulted in loss of significance for adiponectin.   
Conclusions:  This study provides evidence that adipokines are associated with men’s future 
type 2 diabetes risk but not independently of other risk factors.  
 
Keywords: adiponectin, leptin, type 2 diabetes, prospective study 
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1. Introduction 
In the last decade, the prevalence of type 2 diabetes has risen dramatically throughout the 
world.  In the UK alone, the prevalence of diagnosed cases of diabetes is 6% [1].  Although 
significant advances have been made in the treatment of type 2 diabetes, much attention is 
now focusing on preventive measures as a means of helping to curb this epidemic.  Early 
identification of individuals at increased risk of type 2 diabetes is a key priority for effective 
targeting of preventive measures.   
 Obesity is widely acknowledged as being a major risk factor for type 2 diabetes.  
Although the aetiological mechanism by which obesity increases the risk of type 2 diabetes is 
not fully established, it is believed that adipokines, biologically active molecules secreted by 
adipose tissue, may play an important pathophysiological role through their association with 
obesity-induced inflammation and signalling pathways.  Leptin and adiponectin are two 
adipokines that have generated considerable research interest.  Leptin is a pro-inflammatory 
adipokine and is closely correlated to obesity severity [2]. Adiponectin, in contrast to leptin, 
has anti-inflammatory and anti-atherogenic properties, and has been shown to have a positive 
influence on insulin sensitivity [3-5].  
 The evidence regarding the association between leptin and type 2 diabetes risk is 
conflicting, with some studies showing positive associations [6-11] and others showing no 
association [12-15].  Similarly, the association between adiponectin and type 2 diabetes risk 
has not yet been fully elucidated.  A meta-analysis of 13 prospective studies published in 
2009 concluded that increased levels of adiponectin were associated with a reduced risk of 
incident type 2 diabetes [16].  However, generalising the findings is problematic, as most of 
the studies included in the meta-analysis were conducted in Japanese, Pima Indian, Asian 
Indian or Aboriginal Canadian population groups.  More recent European based prospective 
studies have not identified an independent association between adiponectin and type 2 
diabetes [11, 17].  However, many of the prospective studies conducted to date, have had 
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relatively short follow-up periods (range 3.2 y – 8 y) [10, 17, 18], small numbers of cases of 
incident diabetes during follow-up (n = 82) [11], or have failed to fully adjust for important 
confounding factors, such as measures of insulin resistance [11].    
Despite the increasing prevalence of type 2 diabetes in the UK, relatively few UK-
based prospective studies [7, 10] have examined the association between adipokines and 
incident diabetes.  There is also continued debate over the role of adiponectin and leptin as 
independent clinical markers of type 2 diabetes risk.  The aim of this study was to examine 
the association between adiponectin and leptin and the subsequent diagnosis of type 2 
diabetes in a UK population based cohort of non-diabetic middle-aged men. 
 
2. Methods 
2.1. Study population 
The Prospective Epidemiological Study of Myocardial Infarction (PRIME) study is an 
ongoing population-based cohort study examining cardiovascular disease and associated risk 
factors in men from Northern Ireland.  Sampling procedures and study design have been 
described fully elsewhere [19].  In brief, baseline data were obtained between 1991 and 1994 
from 2745 men aged 50 - 60 y.  Participants were recruited from industry, the civil service 
and general medical practices and represented approximately 5% of the male population of 
the greater Belfast area.  The sampling framework was designed so that participants would 
broadly match the social class structure of the background population [19].  Written consent 
was obtained from all participants at baseline and ethical approval was obtained from the 
Research Ethics Committee of the Faculty of Medicine, Queen’s University Belfast. 
 
2.2 Baseline data collection 
Standardised self-report questionnaires were used to assess demographic and socioeconomic 
background including medical history, occupation, dietary habits, smoking and drinking 
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habits and physical activity.  Physical activity was based on the average weekly net energy 
expenditure from physical activity, expressed in metabolic equivalents (MET) hour/week 
[20].  Smoking status was divided into current, former or never smoked.  Socio-economic 
status was based on two measures: fifths of deprivation of the geographical area of the home 
address based on the Northern Ireland Multiple Deprivation Measure 2001 
(www.nisra.gov.uk/deprivation/nimdm_2001.htm) and a composite score of material 
conditions in the household based on three proxy indicators (the type of living 
accommodation (rented or owned/mortgage), the number of cars/vans/motorcycles in the 
household and the number of baths and/or showers and toilets in the home) [20].   
 
A physical examination was carried out to obtain anthropometric measurements including 
body weight (to the nearest 200g), height (to the nearest cm) and waist and hip circumference 
(to the nearest 0.5cm).  Body mass index (BMI) was computed as weight/height2 (kg/m2).  
Both waist:hip ratio (WHR) and BMI have previously been shown to be strong predictors of 
type 2 diabetes [21, 22].  Systolic and diastolic blood pressure was the average of two 
measurements in the sitting position using an automatic sphygmomanometer (Spengler SP9).   
 
2.3 Biological measurements 
A fasting blood sample was collected and processed within 4 hours with aliquots frozen at -
80oC until analysis.  Blood samples were analysed for concentrations of leptin, adiponectin, 
lipids, glucose, insulin and CRP.  Circulating concentrations of adiponectin and leptin were 
measured in plasma and serum respectively using an Elisa (R&D Systems, Billerica, MA, 
USA). For quality control purposes, R&D assay internal standards and laboratory internal 
plasma and serum quality controls were used within each 96-well plate.  Serum levels of CRP 
were measured using a Latex immunoassay CRP16 (Abbott, Architect c8000).  The intra-
assay CV for adiponectin, leptin and CRP was 4.5%, 5.4% and 0.9%, respectively, while the 
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inter-assay CV was 16.7%, 8.9% and 0.8%, respectively [23].  Each assay was performed 
according to the manufacturer’s specification.  Fasting plasma glucose concentrations were 
measured using the glucose oxidase technique.  Plasma total cholesterol, HDL cholesterol and 
triglyceride levels were measured by enzymatic techniques using reagents from Boerhinger-
Ingelheim (Mannheim, Germany).  Fasting insulin concentrations were determined using an 
Abbott immunoassay on an Architect i2000 analyser [23].  Laboratory personnel undertaking 
the biochemical analyses were blinded to the sample origin. Insulin resistance was estimated 
using the homeostasis model assessment of insulin resistance (HOMA-IR), which was 
calculated as fasting insulin x fasting glucose / 22.5 (glucose in mmol/L) [24]. 
 
2.4 Pre-existing type 2 diabetes 
Of the 2745 men recruited, participants who reported having a history of diabetes at baseline 
(n=62) were excluded as were participants who had missing baseline fasting glucose 
measurements either due to lack of sample availability (n=611) or who did not fast for at least 
8 hours (n=41).  Also excluded were those who had a fasting baseline glucose concentration 
≥7 mmol/l, the World Health Organisation diagnostic criterion (n=180).  No follow-up was 
available for 12 men and therefore analyses were performed on 1839 men without type 2 
diabetes at baseline.   
 
2.5 Diabetes follow-up 
Between 1991 and 2010, participants were contacted bi-annually by letter and, if necessary, 
by telephone, to complete a clinical event questionnaire in order to obtain information on the 
incidence of new cases of diabetes.  For the purposes of this study, incident diabetes was 
defined as follows: a) a positive response to the question “Since we last contacted you, have 
you been told by a doctor that you have diabetes”, and either b) self-reported use of oral 
hypoglycaemic drugs during follow-up or c) subsequent general practitioner (GP) 
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confirmation of type 2 diabetes.  Positive responses to a) and b) were subsequently validated 
by a questionnaire completed by the participant’s GP.  This questionnaire was also used to 
ascertain whether the participant had type 1 or type 2 diabetes, the date of onset, the type of 
treatment being administered (i.e. oral drugs, insulin or diet) and the location of treatment 
management (GP clinic or hospital).  If an exact day and month of diagnosis was not 
provided, then the midpoint of the year of diagnosis was used.  Participants with self-reported 
diabetes not validated by the GP or by antidiabetic medication were included in the analyses 
as being non-diabetic, but censored at the time of the annual contact preceding their self-
reported diabetes (n=17).  The mean duration of follow-up (SD) was 14.7 (4.7) years.  During 
the follow-up period, there were 408 deaths and these were confirmed by examination of the 
relevant death certificates.  Participants who died were censored for type 2 diabetes at the 
date of last contact. 
 
2.6 Statistical analysis 
Data were summarised as mean and SD except where distributions were positively skewed, in 
which case the variables were logarithmically transformed and results presented as geometric 
mean and interquartile range (IQR).  Chi-square tests were used to compare categorical data 
which included smoking status (never, ex or current), alcohol intake (none, ≤168 ml/wk or 
>168 ml/wk) and physical activity (<47.9, 47.9 - 84.99, 85.0 - 131.3, >131.3 MET hr/wk).  
Pearson correlation coefficients were used to examine associations between adipokines and 
diabetes risk factors.  Cox proportional hazard regression models were used to assess the 
relative risk of type 2 diabetes according to baseline adipokine concentrations.  Participants 
were divided into thirds according to the distribution of adiponectin and leptin 
concentrations, with the lowest third being used as the reference category.  Potential 
confounding factors included in the analyses were established lifestyle risk factors, biological 
risk factors and more novel risk factors known to be associated with type 2 diabetes including 
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HOMA-IR and CRP.  The confounding factors included in the analyses have been previously 
highlighted in the literature as showing strong associations with risk of type 2 diabetes.  
Model 1 was adjusted for age; Model 2 was adjusted for age, BMI and WHR; Model 3 was 
adjusted as for Model 2 plus alcohol, smoking, socio-economic status and physical activity; 
Model 4 was adjusted as for Model 3 plus total cholesterol, HDL cholesterol, triglycerides, 
systolic blood pressure, drug treatment for hypertension and CRP; Model 5 was adjusted as 
for Model 4 plus HOMA-IR.  Survival probabilities at 5, 10 and 15 y were estimated from 
Kaplan-Meier graphs (not shown).  For all analyses, p<0.05 was considered statistically 
significant.  Statistical analyses were performed with SPSS v17.0 for Windows (SPSS Inc, 
Chicago, IL).   
 
3. Results 
During the follow-up period, there were 151 newly reported cases of diabetes.  For 145 men, 
type 2 diabetes was ascertained by self-report questionnaire along with confirmation from 
their family doctor while in the remaining six men diabetes was ascertained by self-report 
questionnaire combined with self-reported use of hypoglycaemic drugs.  
  
Table 1 describes the baseline demographic, anthropometric and metabolic characteristics of 
participants with and without type 2 diabetes at the end of the follow-up period.  The mean 
(SD) BMI of participants was 26.1 (3.3) kg/m2 and 261 (14%) were obese (waist 
circumference >102 cm or BMI ≥30 kg/m2).  The men who developed type 2 diabetes during 
follow-up had a significantly higher BMI at baseline compared to men who did not 
(p<0.001).  Other baseline measures of adiposity, including waist and hip circumference and 
WHR, were also higher in these men and a greater proportion were classified as obese at 
baseline, based on waist circumference >102 cm or BMI ≥30 kg/m2 (all p<0.001).  They also 
had significantly higher baseline systolic and diastolic blood pressure, triglycerides, CRP, 
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glucose concentrations, insulin resistance (HOMA-IR) and leptin concentrations than those 
who did not develop diabetes during the follow-up period (p<0.001) and a greater proportion 
were on drug treatment for hypertension (p=0.002), had lower physical activity levels 
(p=0.001) and had a history of smoking (p=0.03).  Conversely, baseline concentrations of 
adiponectin and HDL cholesterol were significantly lower in those who subsequently 
developed diabetes compared to those who didn’t develop diabetes.  No significant 
differences were evident in baseline age, total cholesterol and alcohol intake between those 
who developed diabetes and those who did not.  However, these factors were retained in the 
relevant regression models as they are well established risk factors for type 2 diabetes.  
 
The cumulative rate for developing type 2 diabetes at 5, 10 and 15 y was 0.5%, 2.7% and 
7.7% respectively.  The incidence rates and adjusted relative risks (RRs) of type 2 diabetes 
according to thirds of adiponectin and leptin distribution are presented in Table 2.  Men in 
the highest category for adiponectin and in the lowest category for leptin had reduced risk of 
developing type 2 diabetes after adjusting for age (model 1).  This association became 
slightly attenuated, but remained significant, after further adjustment for BMI and WHR 
(model 2) and lifestyle factors (model 3).  Further adjustment for biological risk factors, 
including CRP (model 4), resulted in loss of significance for leptin.  Model 4 remained 
statistically significant for adiponectin, but, when further adjusted for HOMA-IR, although 
men who were in the highest third for adiponectin had a 46% reduced risk of developing type 
2 diabetes compared to those in the lowest third, this association was no longer significant 
(model 5).  There were no significant interactions between the categories of leptin or 
adiponectin and type 2 diabetes.  There was also no evidence of an interaction between 
adiponectin or leptin and HOMA on type 2 diabetes risk.   
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4. Discussion  
In this prospective, population-based study of non-diabetic middle-aged men, low 
concentrations of adiponectin and high concentrations of leptin were associated with a higher 
risk of developing type 2 diabetes independent of age, BMI, WHR and socioeconomic 
factors.  However, after adjustment for biological risk factors, including lipids, blood pressure 
and CRP, the significant association between leptin and diabetes risk disappeared.  Additional 
adjustment for HOMA-IR, an indirect marker of insulin resistance, also resulted in loss of 
significance for the association between adiponectin and type 2 diabetes risk.   
 
Previous epidemiological evidence regarding the association between leptin and the onset of 
type 2 diabetes is somewhat conflicting.  High levels of leptin have been shown to be 
independently associated with diabetes in some [8-11] but not all studies [7, 12-15, 18].  Of 
these studies, only two were UK population based studies [7, 10].  Welsh et al [10] reported a 
positive association between leptin and type 2 diabetes in men, but not women, after 
adjusting for confounding factors.  In contrast, another UK based study by Wannamethee et 
al [7] showed no independent association between leptin and subsequent diabetes.  Instead, 
they reported that obesity and insulin resistance explained most of the association between 
leptin and subsequent diabetes risk.  Other studies also suggest that abdominal adiposity may 
modulate the association between leptin and type 2 diabetes [9, 12, 14, 15, 25].   
 
The evidence regarding the association between adiponectin and type 2 diabetes is also 
conflicting.  In contrast to the findings of the current study, a meta-analysis of 15 prospective 
studies by Li and colleagues [16] showed an inverse association between plasma adiponectin 
and risk of type 2 diabetes, however not all of the studies included in that meta-analysis 
adjusted for markers of insulin sensitivity.  Consistent with our findings, a number of other 
prospective studies which did adjust for other biological factors, such as markers of insulin 
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sensitivity found no independent association between low adiponectin levels and increased 
type 2 diabetes risk [11, 17, 18, 26].  The current study also found no evidence of an 
interaction between adiponectin and insulin resistance. Another recent study by Lilja et al 
[27] reported that high adiponectin levels were associated with decreased risk of type 2 
diabetes in both insulin-sensitive and insulin-resistant individuals.   In contrast, a study by 
Hivert et al [28] observed that adiponectin offered greater protection in insulin resistant men 
than in insulin sensitive men.  The reason for the inconsistency in results across the studies is 
not clear. The attenuating effect of HOMA on the relationship between adiponectin and Type 
2 diabetes, as observed in the current study, could also suggest that insulin resistance is acting 
as a mediator on the pathway between adiponectin concentrations and type 2 diabetes 
development.  
 
The mechanism by which adiponectin affects glucose tolerance is not yet fully understood 
but it has been attributed to its insulin-sensitizing and anti-inflammatory properties [4, 5].  A 
decrease in adiponectin is believed to precede the onset of insulin resistance [4], but this has 
not yet been proven and has also been questioned [28].  It remains unclear whether 
adiponectin has a causal effect on diabetes or is simply acting as a surrogate marker for some 
other metabolic risk factor(s).  Unlike adiponectin, persistently high levels of leptin exert pro-
inflammatory effects and are involved in upregulating other cytokines associated with insulin 
resistance and type 2 diabetes [29].  Recent evidence has highlighted that chronic 
inflammation may be an important contributory factor in the pathogenesis of type 2 diabetes 
[30-32] through its effects on insulin sensitivity and insulin secretion.   
 
Strengths of the current study include the prospective design and the long follow-up period 
(14.7 ± 4.7 y).  The results presented are representative of a UK based population, for which 
there is relatively limited data available relating to the association between adipokines and 
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onset of diabetes.  Unlike a number of previous studies which were limited in their ability to 
adjust for important confounding factors, the current study included a wide range of 
biological and lifestyle covariates, particularly measures of adiposity and insulin resistance.   
 
Limitations of the study include its observational design and the high number of deaths 
during follow-up which may have resulted in selection bias.  During the follow-up period 
there were 408 deaths recorded (22%).  Another limitation is that the participants were all 
middle-aged to older men, therefore it is difficult to generalise the findings to women or 
younger age groups.  It is also possible that some cases of diabetes were missed at baseline, 
as an oral glucose tolerance test was not carried out.  Moreover, HbA1C which is a clinical 
indicator of blood glucose concentration and is commonly used for identifying people with 
diabetes was not measured.  In addition, adiponectin and leptin were only measured at 
baseline and therefore we cannot rule out the possibility of change in these parameters over 
time.  A further limitation, in common with all observational studies, is the possibility of 
residual confounding or failure to include other potential confounders.  
 
5. Conclusion 
 In summary, after adjusting for potential confounding factors, neither high leptin nor 
low adiponectin concentrations were independent predictors of increased risk of type 2 
diabetes among healthy middle-aged men.  Indeed, the associations observed between leptin, 
adiponectin and incident type 2 diabetes were largely explained by biological factors and 
insulin resistance, respectively.  This study challenges the findings from previous studies 
which observed statistically significant associations between adipokines and onset of type 2 
diabetes and suggests that such findings may have been due to a failure to adequately adjust 
for confounding factors, such as insulin resistance.   
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Table 1: Baseline characteristics of participants according to diabetes status at follow-up 
 
 Developed diabetes  
 No (n=1688) Yes (n=151) p value 
Age (y) 54.8 (2.9) 55.1 (2.8) 0.21 
BMI (kg/m2) 25.9 (3.2) 28.4 (3.6) <0.001 
n (%) obese (i.e. waist>102cm 
or BMI ≥ 30kg/m2) 
215 (12.7) 46 (30.5) <0.001 
Waist (cm) 90.6 (8.8) 96.5 (9.1) <0.001 
Hip (cm) 96.4 (6.4) 100.0 (7.8) <0.001 
Waist:hip ratio 0.94 (0.05) 0.97 (0.05) <0.001 
Smoking status n (%): 
- Never 
- Former 
- Current 
 
581 (34.4) 
585 (34.7) 
522 (30.9) 
 
43 (28.5) 
69 (45.7) 
39 (25.8) 
 
0.03 
Alcohol intake n (%): 
- Teetotal 
- ≤ 168g/wk (≤ 21 units) 
- > 168g/wk 
 
668 (39.6) 
475 (28.1) 
545 (32.3) 
 
63 (41.7) 
43 (28.5) 
45 (29.8) 
 
0.81 
Total physical activity (MET 
hr/wk) n (%)  
- < 47.9 
- 47.9 – 84.99 
- 85.0 – 131.3 
- >131.3 
- Unknown 
 
 
359 (21.3) 
382 (22.6) 
374 (22.2) 
383 (22.7) 
190 (11.2) 
 
 
46 (30.5) 
24 (15.9) 
30 (19.9) 
23 (15.2) 
28 (18.5)  
 
 
0.001 
SBP (mmHg) 132.1 (20.2) 139.9 (22.2) <0.001 
DBP (mmHg) 80.9 (11.4) 84.6 (11.6) <0.001 
Hypertensive n (%) 586 (34.7) 80 (53.0) <0.001 
Currently on drug treatment 
for hypertension n (%) 
142 (8.4) 24 (16.6) 0.002 
Adiponectin (µg/ml)  5.08 (3.34, 7.73) 3.61 (2.44, 5.56) <0.001 
Leptin (ng/ml) 4.16 (2.27, 6.84) 7.19 (4.54, 11.87) <0.001 
CRP (mg/L) 1.60 (0.79, 3.04) 2.37 (1.28, 4.52) <0.001 
Fasting glucose (mmol/L) 5.27 (4.91, 5.67) 5.57 (5.15, 6.17) <0.001 
HOMA-IR 1.30 (0.92, 1.86) 2.17 (1.58, 3.06) <0.001 
Triglycerides (mmol/L) 1.65 (1.17, 2.28) 2.29 (1.64, 3.14) <0.001 
20 
 
HDL cholesterol (mmol/L) 1.20 (0.32) 1.03 (0.26) <0.001 
Total cholesterol (mmol/L) 5.88 (1.00) 5.89 (1.03) 0.94 
Excludes participants who had diabetes at baseline 
Continuous variables are presented as mean (SD) or geometric mean (IQR) for skewed variables 
Categorical variables are presented as n (%).  
Differences between groups analysed using independent samples t-test for continuous variables and chi-square test 
for categorical variables 
HOMA-IR, Homeostasis model assessment of insulin resistance 
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Table 2: Relative risk of type 2 diabetes by thirds of adiponectin and leptin in healthy non-diabetic men 
 
 
Rate / 
1000 
person 
years  
Adjusted relative risk (95% CI)  
 
 
Categories  Model 1  Model 2  Model 3  Model 4  Model 5 
Adiponectin (µg/ml)  
  
     
< 3.77 (n = 467)  
 
8.8 1.00  1.00  1.00 1.00 1.00 
3.77 - 6.66 (n = 467)  
 
5.6 0.62 (0.41, 0.93) 0.67 (0.44, 1.00) 0.64 (0.42, 0.97) 0.71 (0.47, 1.09) 0.92 (0.60, 1.43) 
> 6.66 (n = 463)  
 
2.2 0.24 (0.14, 0.42) 0.33 (0.19, 0.58) 0.29 (0.17, 0.52) 0.37 (0.20, 0.67) 0.54 (0.29, 0.99) 
p for trend across thirds  <0.001 <0.001 <0.001 0.001 0.07 
Leptin (ng/ml) 
 
      
< 2.93 (n = 591)  
 
2.5 1.00  1.00 1.00  1.00 1.00 
2.93 - 6.00 (n = 601)  
 
3.9 1.61 (0.95, 2.74) 
 
1.07 (0.62, 1.85) 1.00 (0.58, 1.74) 0.88 (0.50, 1.53) 0.74 (0.43, 1.29) 
> 6.00 (n = 595)  
 
10.2 4.27 (2.67, 6.83) 1.93 (1.13, 3.29) 1.75 (1.02, 3.01) 
 
1.43 (0.77, 2.34) 0.91 (0.51,1.60) 
p for trend across thirds  <0.001 0.004 0.01 0.14 0.99 
Model 1:  Adjusted for age  
Model 2:  Adjusted for age, BMI and waist:hip ratio  
Model 3:  Adjusted for model 2 variables + alcohol status, smoking status, measures of socioeconomic status (includes material conditions and deprivation 
score), physical activity 
Model 4:  Adjusted for model 3 variables + total cholesterol, HDL cholesterol, triglycerides, systolic BP, on drug treatment for hypertension, CRP 
Model 5:  Adjusted for model 4 variables + HOMA-IR 
n = 1397 for adiponectin ;  n = 1787 for leptin  
